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Abstract
Histone deacetylases (HDACs) are key transcription regulators that function by deacetylating histones/transcription factors and modifying
chromatin structure. In this work, we showed that chemical inhibition of HDACs by valproic acid (VPA) led to impaired liver development in
zebrafish mainly by inhibiting specification, budding, and differentiation. Formation of exocrine pancreas but not endocrine pancreas was also
inhibited. The liver defects induced by VPA correlate with suppressed total HDAC enzymatic activity, but are independent of angiogenesis
inhibition. Gene knockdown by morpholino demonstrated that hdac3 is specifically required for liver formation while hdac1 is more globally
required for multiple development processes in zebrafish including liver/exocrine pancreas formation. Furthermore, overexpression of hdac3 but
not hdac1 partially rescued VPA induced small liver. One mechanism by which hdac3 regulates zebrafish liver growth is through inhibiting
growth differentiation factor 11 (gdf11), a unique target of hdac3 and a member of the transforming growth factor β family. Simultaneous
overexpression or morpholino knockdown showed that hdac3 and gdf11 function antagonistically in zebrafish liver development. These results
revealed a novel and specific role of hdac3 in liver development and the distinct functions between hdac1 and hdac3 in zebrafish embryonic
development.
© 2008 Elsevier Inc. All rights reserved.Keywords: Histone deacetylase; Liver; Pancreas; Organogenesis; Zebrafish; VPAIntroduction
Acetylation and deacetylation of histones generate structural
changes in chromatin which play an important role in the
control of gene transcription. Histone acetylation promotes the
formation of a transcriptional competent environment by
‘opening’ chromatin. Conversely, histone deacetylation pro-
motes a ‘closed’ chromatin state and transcriptional repression
(Cheung et al., 2000).
Histone deacetylases (HDACs) deacetylate histones and
certain transcription factors. Eighteen mammalian HDACs have
been identified to date and they are classified into three classes
based on sequence homology to different yeast HDACs. Class I
HDACs (HDAC1, 2, 3 and 8) are most closely related to the⁎ Corresponding author.
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doi:10.1016/j.ydbio.2008.02.034yeast HDAC RPD3. Class II HDACs (HDAC4, 5, 6, 7, 9 and
10) are highly homologous to yeast HDA1. Class III HDACs
are most similar to yeast Sir2 HDAC. While class I HDACs are
expressed in most cell types, the expression pattern of class II
HDACs is more restricted, and has been shown to be involved
in cell differentiation and developmental processes such as
myogenesis (de Ruijter et al., 2003).
Because of the relatively ubiquitous expression pattern of
class I HDACs and the fundamental roles HDACs play in
regulating chromatin structure, it was perceived that class I
HDACs would play a general role in embryonic development.
However, recent findings indicate otherwise. Global gene
expression profiling in C. elegans identified tissue-specific
and extracellular matrix (ECM)-related genes as major HDAC1
targets (Whetstine et al., 2005). In mouse, HDAC1 and 2 are
expressed in the prospective epithelium of the developing
intestine, regulating intestine epithelial differentiation (Tou et
al., 2004). Recently, HDAC3 expression was reported to be
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intestine and colon (Wilson et al., 2006). In zebrafish, hdac1
has been shown to play specific roles in neurogenesis,
craniofacial cartilage and pectoral fin development (Cunliffe,
2004; Phiel et al., 2001; Yamaguchi et al., 2005). However, the
functions of other class I HDACs in zebrafish embryonic
development are not known.
Recently, significant advances have been made in our
understanding of the molecular mechanisms that control
vertebrate liver development. During early development of
the zebrafish digestive system, a number of buds emerge from
the gut primordium, giving rise to different organs including
liver and pancreas (Field et al., 2003). Initial patterning events
define the liver precursors within the foregut endoderm. This
hepatic primordium later forms a morphologically distinct bud
at around 28–30 hpf that grows out from the foregut. The
growth phase follows the completion of budding and is
characterized by change in liver size and shape. However, a
lot still remains unknown of liver organogenesis. In mouse,
early liver budding requires mesodermal inductive signals such
as fibroblast growth factors (FGFs) from the adjacent
cardiogenic mesoderm and bone morphogenic proteins
(BMPs) from nearby septum transversum mesenchyme. In
addition, interaction with endothelial cells is also crucial
although the signaling molecules from endothelial cells are not
known at the moment (Zaret, 2002). In contrast, endothelial
cells are not necessary for liver budding in zebrafish because in
the mutant cloche which lacks most endothelial cells, liver buds
normally (Field et al., 2003).
HDAC inhibitors have been reported to induce Hepatoma
cell growth arrest, apoptosis and hepatocyte differentiation in
vitro, but their role in hepatocyte differentiation in vivo has
not been investigated (Herold et al., 2002; Yamashita et al.,
2003).
In this work, we analyzed the roles of HDACs, in
particular hdac1 and hdac3, in zebrafish embryonic develop-
ment especially liver development. We found that inhibiting
HDACs with HDAC inhibitors valproic acid (VPA) and
Trichostatin A (TSA) not only led to defects in angiogenesis,
but also interfered with liver and exocrine pancreas formation,
while the endocrine pancreas was not affected. Hepatoblast
markers (prox1, hhex, foxa3) were absent or severely reduced
in the liver region in treated embryos, while marker genes for
hepatocyte differentiation ceruloplasmin (Cp) and liver faty
acid binding protein (lfabp) were not expressed in liver until
4–5 dpf. We demonstrated that the liver defects are not related
to the vascular defect. Gene knockdown with morpholino
antisense oligonucleotide (MO) indicated that although both
hdac3 and hdac1 are required for liver formation in zebrafish,
hdac3 plays a more specific role. We further demonstrated
that one mechanism of hdac3 function is by suppressing
growth differentiation factor 11 (gdf11) gene, a negative
regulator of cell proliferation and a specific transcriptional
target of hdac3 (Zhang et al., 2004). Our results provide the
first evidence that HDACs are required for liver/exocrine
pancreas formation and revealed a novel role of hdac3 in liver
organogenesis.Materials and methods
Zebrafish and embryos
Local outbreed wild type (WT) as well as transgenic lines of zebrafish and
embryos was maintained, collected and staged as described (Westerfield, 1995).
Transgenic lines used are Tg(lfabp:RFP; elaA:EGFP) containing liver-specific
liver fatty acid binding protein (lfabp) promoter controlled RFP and exocrine
pancreas-specific elastase A (elaA) promoter controlled EGFP (Her et al., 2003;
Wan et al., 2006); Tg(fli-1:EGFP) in which GFP is expressed in endothelial cells
(Lawson and Weinstein, 2002).
Treatment of embryos with inhibitors of HDACs and angiogenesis
VPA (Sodium 2-propylpentanoate) and TSA were purchased from Sigma
Aldrich, and Valpromide (VPM, Dipropylacetamide) was a kind gift from
Katwijk Chemie BV, Netherlands. Angiogenesis inhibitors SU5614, SU1498,
2-methoxyestradiol and Genestein were purchased from Calbiochem. Embryos
were raised up to the shield stage and HDAC or angiogenesis inhibitors
were then added to embryo water (RO water supplemented with 40 mg/ml
ocean salt) after dissolving either in water (VPA) or DMSO (TSA, SU5614,
SU1498, 2-methoxyestradiol and Genestein). The embryo water was replaced
every day with fresh chemicals. Images were acquired using Zeiss Axiovert
200 fluorescent microscope equipped with Axiocam digital camera. Confocal
Z-stack images were acquired using Olympus Fluoview FV1000.
Whole mount in situ hybridization (WISH)
WISH was performed with digoxigenin labeled antisense RNA probes for
the following genes: cp (Korzh et al., 2001), foxa3 (Field et al., 2003), hhex
(Wallace et al., 2001), hdac3 (gene accession number NM_200990.1), gdf11
(gene accession number NM_212975), prox1 (Liu et al., 2003), insulin, elas-
tase B (Mudumana et al., 2004) according to the zebrafish book. The embryos
were grown in 1-phenyl-2-thiourea (PTU) solution to block pigmentation.
HDAC enzymatic activity measurement
In order to measure the HDAC enzymatic activity in zebrafish embryos,
protein extracts were isolated from wild type and VPA-treated embryos from a
pool of about 100 embryos at required developmental stage using protein
extraction reagent (Pierce, Rockford, IL) supplemented with protease inhibitor
(Roche, Indianapolis, IN) and homogenized for 15 s (sigma ultra disintegrator).
Samples were then centrifuged for 15 min at 10,000 rpm 4 °C. Clear
supernatants were collected. HDAC fluorescent activity assay was performed
according to the manufacturer's instructions using a unique substrate (Biomol,
Plymouth Meeting, PA), which contains an acetylated lysine side chain. Fluor de
Lys substrate was incubated with 20 μg of protein extract for 30 min at 37 °C,
and the product produced was measured using SPECTRAmax GEMINI XS
microplate spectrofluorometer with the SOFTMAX PRO V.3.1.2 system
(Molecular Devices) with excitation at 355 nm and emission at 460 nm with a
cut off filter of 455 nm. Assay was repeated thrice and the average arbitrary
florescence units (AFU) were represented as total HDAC activity.
HDAC activity in the hdac1 or hdac3 morphants was similarly determined
from embryos obtained from wild type fish and Tg(lfabp:RFP; elaA:EGFP).
Same amount of 5 bp mismatch morpholino injected embryos were used as
control. In case of transgenic line, embryos were screened for liver defects based
on the RFP expression, and protein extracts were collected from the pools of
around 50 embryos at 3 dpf. To get rid of the background fluorescence activity
from the transgenic embryos, fluorescence in the mismatch morpholino injected
embryos was used to normalize the background fluorescence.
Real-time RT-PCR
Total RNAwas extracted using RNAwiz™ (Ambion, USA). Real-time RT-
PCR was performed using QuantiTect SYBR Green RT-PCR kit (Qiagen, USA)
using Opticon 2 real-time PCR machine (MJ Research, USA) and analyzed
using Opticon 2 software. Ct values were normalized against β-actin and fold
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2001). The primers used are: gdf11: Forward 5′ CGT CAT CAC AAT GGC
TTC AGA, Reverse 5′ TTG AAG AAA CAA CAG GTC GGT TT.
Molecular cloning
Full length cDNAs for hdac1 (NM_173236.1), hdac3 (NM_200990.1) and
gdf11 (NM_212975) were obtained by high fidelity PCR using Advantage High
Fidelity 2 (HF2) PCR kit (Clontech, USA) and a full length zebrafish embryonic
cDNA library as template. The following sets of primers were used: hdac1
Forward 5′-CGG GCA GGC GCA GGC TGTAAT T-3′, Reverse 5′-CAT GCA
TCC AGG AGG ACT GGC-3′; hdac3 Forward 5′-CGG CAA CAT GAC CAA
TCGAAC TGC G T-3′, Reverse 5′-CGC TTT TAC CCA CACATCACAGTC
AAG-3′; gdf11 Forward 5′-CGATGA AAA GGTATA ACT TTTA-3, Reverse
5′-CCA CTC TCC CCC CTC CCT TAC T-3′. The PCR products were cloned
into pGEM-T easy vector (Promega) and confirmed by sequencing. For
functional analysis, these genes were subcloned into pCS2 vector.
Gene knockdown by MO microinjection
MOs were purchased from Gene Tools (Philomatch, USA), and were diluted
in sterile water at the concentration of 1 mM. They were designed to overlap the
translational start site of the following genes: hdac3 antisense 1: CATAGAAG-
TACGCAGTTCGATTGGT, antisense 2: GCAGTTATTTCTAGCACGA-
GAAAC, 5 bp mismatch control: CATAcAAcTACcCAGTTCcATTcGT;
hdac1 antisense: TTG TTC CTT GAG AAC TCA GCG CCAT, 5 bp mismatch
control: TTc TTC CTT cAG AAg TCA cCG CgAT; gdf11 antisense: ATA CCT
TTT CAT GTT GTTAAATAT C, 5 bp Mismatch: ATA gCT TTT gAT cTT cTT
AAA aAT C and vegf antisense: GTATCAAATAAACAACCAAGTTCAT, 4 bp
mismatch control: GTAaCAAtTAAACA ACCAtGTTgAT. For single knock-
down, hdac1 MO used is 3 or 6 ng/embryo and hdac3 MO used is 12 ng/
embryo. For double knockdown with hdac1 and hdac3, both morpholinos were
combined (hdac1, 3 ng/embryo; hdac3, 12 ng/embryo) and injected into 1–2
cell stage embryos. To rescue hdac3morphants (12 ng/embryo), zebrafish gdf11
gene was co-knocked down by co-injecting gdf11 MO (4 ng/embryo).
mRNA rescue and overexpression
To rescue the VPA-treated embryos, hdac1 and hdac3 5′-capped mRNA
was synthesized using m messenger m machine kit (Ambion, USA) and injected
singularly or together into Tg(lfabp:RFP; elaA:EGFP) embryos at 1–2 cell
stages. The injected embryos were raised to shield stage and divided into two
groups, one group of embryos were then treated with VPA (10 μM) and the other
group remained untreated control embryos. The embryos were raised to 5 dpf
with fresh VPA in embryo water changed daily. To rescue VPA-treated embryos,
hdac1 mRNA (0.3 ng/embryo) and hdac3 mRNA (0.3 ng/ml) were injected
singularly or together. To rescue gdf11 mRNA overexpression embryos (0.5 ng/
embryo), hdac3 mRNA (0.3 ng/embryo) was co-injected.
Results
HDACs are required for liver and exocrine pancreas formation
in zebrafish
To investigate the role of HDACs in the organogenesis of
liver/pancreas, we used valproic acid (VPA), a potent HDAC
inhibitor which preferably inhibits class I HDACs, to treat
zebrafish embryos at non-terotogenic concentrations (Pillai et
al., 2004). Embryos from transgenic line Tg(lfabp:RFP; elaA:
EGFP) which express RFP in liver (from 59–60 hpf onward)
and GFP in exocrine pancreas (from 4 dpf onward) were treated
with VPA (20 μM and 10 μM) from shield stage and the effects
on liver formation were observed from 60 hpf onward. As
shown in Fig. 1, in VPA-treated embryos, RFP could not bedetected up to 4 dpf (∼100% embryos, n=320–350) (Fig. 1a,
panels A–F), suggesting the absence of liver in these embryos.
RFP positive liver was only observed at 5 dpf, and the liver size
is much smaller compared to control embryos at the same stage.
Furthermore, liver remained the same size from 5 dpf to 8 dpf
(data not shown). VPA interfered with liver formation in a dose-
dependent manner. Under lower VPA concentrations (5 μM and
1 μM), RFP expression in liver could be observed at normal
developmental stages (3 dpf), but the size of liver was much
smaller (n=250–300) (data not shown). VPA also inhibited
angiogenesis in zebrafish embryos, consistent with its anti-
angiogenic activity reported earlier (Michaelis et al., 2004). The
intersegmental vessels (ISVs) in the developing zebrafish
embryos which are generated through angiogenesis either did
not form or never connected to dorsal longitudinal anastamotic
vessels (DLAVs) (Fig. 1a, compare panels G and H).
The effect of HDAC inhibition on liver formation was also
confirmed by expression of ceruloplasmin (Cp), an early liver
differentiation marker, by WISH. In VPA-treated embryos, Cp
expression in liver was severely delayed, with no expression up
to 72 hpf comparing to the normal expression which starts from
32 hpf (100% of embryos, n=200 embryos) (Fig. 1b, panels A–
F). In contrast, Cp expression in YSL was not affected (Fig. 1B,
panels D and F). At 4 dpf, a tiny Cp positive area was observed
in about 30% (n=200) of VPA-treated embryos (Fig. 1B, panel
H) whereas the majority (70%) of embryos still did not express
Cp. At 5 dpf, Cp expression appeared in all VPA-treated
embryos, but the liver was much smaller compared to untreated
embryos at the same stage (Fig. 1b, panel J) (100% of embryos,
n=200).
The formation of exocrine pancreas was also affected by
VPA, with a delayed GFP expression in exocrine pancreas only
observable at 5 dpf (100% embryos, n=100). The exocrine
pancreas was also of much smaller size at this stage compared to
control embryos (Fig. 1c, compare panels A vs. B and C vs. D).
In contrast, development of endocrine pancreas marked by in-
sulin (ins) expression from 2 dpf to 5 dpf was not affected by
VPA (Fig. 1c, panels E–J) (100% embryos, n=100).
As earlier reports of the teratogenic effects of VPA on
zebrafish embryos were observed at very high doses often in
mM concentrations, we want to confirm the effectiveness of the
low level VPA (20 μM) used in our experiments in inhibiting
HDACs. Wild type embryos were treated with VPA and total
HDAC enzymatic activity was measured from 15 somites to
5 dpf using a florescent based HDAC enzymatic activity assay
(Fig. 2a). Total HDAC enzymatic activity in untreated embryos
was found to gradually increase from 15-somite stage (about
16.5 hpf) and reached the highest level at 2 dpf and gradually
decreasing from 3 dpf to 5 dpf. VPA at 20 μM effectively
suppressed HDAC enzymatic activity at all the stages
observed, with suppression of more than 75% at 2 dpf and
3 dpf (Fig. 2a). At 20 μM or lower, VPA is non-terotogenic in
the first 3 days of embryonic development with no gross
developmental deformities or retardation observed. However,
from 3 dpf onward, small head and mild pericardia edema were
observed, with morphological deformation more severe at later
stages (Fig. S1).
Fig. 1. HDACs are required for liver and exocrine but not endocrine pancreas formation. (a) Embryos from Tg(lfabp:RFP; elaA:EGFP) and Tg(fli-1:EGFP) were
treated from shield stage with VPA (20 μM) as described in Materials and methods. Liver formation was examined by the appearance of red fluoresce (white arrows) at
3 dpf (A), 4 dpf (C) and 5 dpf (E and F). In VPA-treated embryos, liver was not formed up to 4 dpf as judged by the absence of red fluorescent, while a much smaller
liver emerged at 5 dpf (E and F). Blood vessel was monitored by green fluorescence and ISV defect is indicated by thin white arrow (G, H). (b) Liver formation
analyzed by liver differentiation marker Ceruloplasmin (cp) expression at various stages of liver formation including 32 hpf (A, B) and 48 hpf (C, D), 3 dpf (E, F),
4 dpf (G, H) and 5 dpf (I, J). Cp expression was absent in liver (white arrow) in VPA-treated embryos up to 3 dpf although its expression in YSL (white arrowhead) was
not affected (C, D, E and F). A small number of liver cells start to express Cp at 4 dpf which grew, but never reached the control liver size at 5 dpf (I vs. J). All the
images are dorsal views, anterior to the left. (c) Liver and exocrine pancreas formation analyzed in transgenic line and endocrine pancreas formation analyzed by
insulin expression. Panels A–D are merged images of z-stack taken by confocal microscope. Liver (in red) is indicated by a thick white arrow and exocrine pancreas (in
green) by a thin white arrow. Endocrine pancreas (black arrow, E–J) as indicated by insulin (ins) expression was not affected by VPA treatment from 2 dpf to 5 dpf. All
the images are dorsal views, anterior to the left. Scale bar represents 100 μm for all panels except in panel aG, which represent 30 μm and panel cA, which represents
50 μm.
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defects observed in VPA-treated embryos, embryos were treated
with a structurally unrelated HDAC inhibitor TSA which
inhibits both Class I and II HDACs (Pillai et al., 2004), as well
as Valpromide (VPM), a structural analogue of VPAwhich does
not inhibit HDAC. Liver formation and growth were not
affected in embryos treated with VPM at all the stages observed
(Fig. 2b, panels C, E and H), whereas liver formation andgrowth were inhibited in embryos treated with TSA (Fig. 2b,
panels B, D and G). Similar to VPA, TSA treatment leads to
delay of RFP appearance in liver until 5 dpf and a much smaller
liver was observed compared to control. We therefore
concluded that liver defects in VPA-treated embryos were due
to inhibition of HDACs. HDAC(s) are required for organogen-
esis of liver and exocrine pancreas but not endocrine pancreas in
zebrafish.
Fig. 2. The liver defects in VPA-treated embryos correlated with inhibition in HDAC enzymatic activity. (a) HDAC enzymatic activity in zebrafish embryos were
measured by fluorescent based assay. Embryos were treated (from 15-somite stage) with VPA (20 μM) and harvested at different stages. Total HDAC enzymatic
activity was inhibited from 1 dpf onward and maximum reduction (around 75%) was observed at 2–3 dpf in VPA-treated embryos. (b) Embryos from Tg(lfabp:RFP;
elaA:EGFP)were treated with TSA (B, D, G), a structurally unrelated HDAC inhibitor, and Valpromide (VPM) (C, E, H), a structural analogue of VPAwhich does not
inhibit HDAC. Liver formation was observed at 3 dpf (A–C), 4 dpf (D–E) and 5 dpf (F–H). No liver was observed in TSA-treated embryos up to 4 dpf (B, D) while a
small liver appeared at 5dpf (G, white arrow). Liver formation was unaffected in VPM-treated embryos (C–H, white arrows). All the images are lateral view, anterior to
the left. Scale bar is 50 μm.
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inhibition of angiogenesis
Since angiogenesis inhibition in vitro by VPA is preceded by
histone hyperacetylation (Michaelis et al., 2004), it is possible
that the delay in liver formation is an indirect result of the blood
vessel defect. In addition, VPA suppresses the expression of
vascular endothelial growth factor (VEGF) in cultured cancer
cells, a key angiogenic growth factor regulating embryonic
vascular development in zebrafish (Liang et al., 2001;
Nasevicius et al., 2000; Zgouras et al., 2004). Indeed, VPA
also inhibited VEGF production at both mRNA and protein
levels in zebrafish embryos (data not shown). While vascular-
ization is essential for liver formation in mouse (Zaret, 2002), it
is not clear if a similar requirement also occurs in zebrafish.Earlier report of normal liver budding in the zebrafish mutant
cloche which lacks most of the endothelial and hematopoietic
lineages suggests that vascularization may not be required in
zebrafish liver formation (Field et al., 2003; Liao et al., 1997;
Stainier et al., 1995).
To clarify this, specific angiogenesis inhibitors SU5614 and
SU1498 were used to inhibit angiogenesis and their effects on
liver formation were analyzed; both SU5614 and SU1498 are
known to inhibit VEGFR1/Flk-1 tyrosine kinase signaling
(Mendel et al., 2000). In order to observe the angiogenesis
defects and liver formation in the same embryo, Tg(fli-1:EGFP)
(Lawson and Weinstein, 2002), which expresses GFP in blood
vessels, was crossed with Tg(lfabp:RFP, elaA:EGFP), and
embryos were screened for homozygous expression of all three
transgenes and stable line was generated and herein will be
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experiment.
In zebrafish, the subintestinal vein (SIV) branches to hepatic
portal vein around 72 hpf, penetrates and vascularizes liver at
this stage (Isogai et al., 2001) (Figs. 3A–D). At 5 dpf, a highly
vascularized liver can be seen in control embryos (Fig. 3D). In
VPA-treated embryos, SIV was never formed during the
observation period (up to 8 dpf). At 5 dpf, blood vessels were
substantially reduced or absent in liver (Fig. 3H) and the size of
liver was significantly reduced. Blood circulation in treated
embryos was normal up to 3 dpf, but circulation becomes
slower at 4 dpf and was completely undetectable from 5 dpf
onward with obvious cardiac edema (Fig. 3 and data not
shown).
Both SU5614 and SU1498 (5 μM) inhibited angiogenesis
with ISVs either did not form or formed abnormally (Figs. 3I
and M). At 3 dpf, SIV was either absent or defective in treated
embryos. However, not only was normal liver observed in these
embryos at 3 dpf, but it also grew bigger from 3 dpf to 5 dpf
despite the abnormal shape of the embryo (Figs. 3I–P). Similar
phenotypes were also observed in two other angiogenesis
inhibitors (2-methoxyestradiol and Genestein) treated embryos
(data not shown). In addition, zebrafish vegf gene was knocked
down by MO microinjection and liver formation is also
generally normal in vegf morphants (data not shown; Liang et
al., 2001; Nasevicius et al., 2000). The levels of angiogenesis
inhibition judged by ISV abnormality by these chemicalFig. 3. Liver formation in zebrafish does not require vascularization. Zebrafish embry
intersomatic blood vessels (ISV) (thin white arrows) and subintestinal blood vessels (
on 5 dpf and no or minimum liver vascularization was observed (H). Similar angio
SU5614 (5 μM, I–L) and SU1498 (5 μM, M–P). However, liver (thick white arrow
embryos (I–P). All images are lateral view, anterior toward left. The images D, H, L a
and 30 μm in panel D.inhibitors were similar to that of VPA. It is noted that blood
circulation was normal up to 3 dpf in chemical-treated embryos
(data not shown). Altogether, these results demonstrate that the
liver defects induced by HDAC inhibitors are most likely results
of reduced HDAC activity rather than defective vascularization.
Liver development and growth in zebrafish do not seem to
depend on liver vascularization.
HDACs are required for early liver formation
In zebrafish, liver and posterior pancreas bud emerges from
the anterior gut endoderm around 24–28 hpf and liver
development involves multiple stages including specification,
budding, differentiation and growth. To determine which stage
(s) HDAC function is critically important, embryos were treated
with VPA for short and defined intervals at different develop-
mental stages crucial for liver formation and compared with
embryos under VPA continuously. In addition to observe liver
phenotype in Tg(lfabp:RFP; elaA:EGFP), expression of
hepatoblast markers hhex and prox1, endoderm marker foxa3
and liver differentiation marker Cp were also investigated.
We noted that the delay in liver appearance in VPA-treated
Tg(lfabp:RFP; elaA:EGFP) embryos depended on the devel-
opmental stages the treatment was initiated (Table 1A). Delays
in liver formation in this transgenic line were observed only
when VPA treatment was initiated between shield to 15-somites
stage (6 hpf to 16 hpf) (Table 1A and data not shown). A shortos from triple transgenic line were treated with VPA (20 μM). Severe defects in
SIV) (wide white arrow) were observed up to 5 dpf (E–H). Liver only appeared
genesis defects were observed in embryos treated with angiogenesis inhibitors
s) formed normally on 3 dpf and grew extensively from 3 dpf to 5dpf in these
nd P are confocal images of merged z-stacks. The scale bar is 100 μm in panel A,
Table 1A
Summary of the effect of VPA treatment time on liver formation in Tg(lfabp:
RFP; elaA:EGFP) zebrafish embryos
Treatment
start time
Treatment
end time
No. of embryos Liver in Tg(lfabp:RFP; elaA:EGFP)
– – N500, n=5 Liver appears at 3 dpf,
grows larger to 5 dpf,
6 hpf 5 dpf 350, n=5 Delayed appearance, no liver
up to 4 dpf, small liver at 5 dpf
6 hpf 18 hpf 200, n=2 Delayed appearance, no liver
at 3 dpf, small liver at 4 dpf,
remain small to 5 dpf
24 hpf 5 dpf 200, n=2 Small liver at 3 dpf, remained
small to 5 dpf
24 hpf 48 hpf 200, n=2 Small liver at 3 dpf, remained
small to 5 dpf
48 hpf 5 dpf 200, n=2 Small liver at 3 dpf, remained
small to 5 dpf
48 hpf 3 dpf 200, n=2 Small liver at 3 dpf, remained
small to 5 dpf
3 dpf 5 dpf 100, n=2 Liver appears at 3 dpf,
grows larger to 5 dpf,
similar to untreated embryos
3 dpf 4 dpf 100, n=2 Liver appears at 3 dpf, grows
larger to 5 dpf, similar to
untreated embryos
RFP positive liver can readily be observed at 3 dpf from this line. “n” indicates
number of experimental repeats. For short period treatment, VPA (20 μM) was
removed after 12 or 24 h of treatment and embryos were grown in normal
embryo water up to 5 dpf. “–”: not applicable.
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delay in liver appearance with a small liver first appearing at
4 dpf and remained small up to 5 dpf. If VPA treatment started
from 24 hpf or later and continued to 5 dpf, a small RFP+ liver
appeared at the normal developmental tempo at 3 dpf. Transient
VPA treatment from 24 to 48 hpf or from 48 hpf to 3 dpf also
both lead to appearance of small RFP+ liver (lfabp expression)
at 3 dpf. Interestingly, even though VPA is removed after
treatment, liver remained small up to 5 dpf (Table 1A). When
VPA is present from 3 dpf to 4 dpf, liver developed normally
and grew larger between 3 dpf and 5 dpf (Table 1A). These
results indicate that VPA inhibits early liver formation when
present during 6–18 hpf, and causing a delay in liver
development. HDACs are most likely required in the specifica-
tion of liver primordium before liver buds from endoderm.
When present from 3 dpf onward, VPA does not inhibit liver
growth and expansion.
When VPA is present continuously from shield stage (6 hpf),
hhex expression at 24 hpf was absent in liver (thick white arrow)
and pancreas (thick black arrow) regions (Fig. 4A vs. C; Table
1B) whereas its expressions in intermediate cell mass (ICM)
(Fig. 4A vs. C, thin black arrow) and notochord (A–D, white
arrowhead) were not affected (100% embryos, n=150). Under
VPA, hhex expression was observed in the anterior endoderm at
this stage (C and D, black arrowhead). Similarly, at 28–30 hpf,
prox1 expression was absent in liver region (Fig. 4E vs. G and F
vs. H, thick white arrow) in VPA-treated embryos whereas its
expressions in lens (E and F) and neurotube (F and H, thin white
arrow) were not affected (100% of embryos, n=∼100). foxa3expression at 28–30 hpf showed that endoderm thickening in
liver region failed to occur in VPA-treated embryos, suggesting
a delay of liver budding (Fig. 4I vs. J, thick white arrow; Table
1B). Meanwhile, foxa3's expression in anterior intestine was
unaffected (Fig. 4J). At 48 hpf, expressions of hhex and prox1
both showed a significantly reduced liver and pancreas (Fig. 4K
vs. L, M vs. N, and Table 1B, 100% of embryos, n=100).
However, foxa3 expression clearly showed that liver and
pancreas have budded by 48 hpf (Figs. 4O and P), indicating
that liver budding, although delayed, can still occur under VPA.
Interestingly, at 48 hpf, the liver size reduction in VPA-treated
embryos revealed by foxa3 expression was smaller than that
revealed by hhex or prox1 expression (Fig. 4O vs. P, compare to
K vs. L and M vs. N; n=100). Therefore, not all foxa3 positive
liver cells have become hepatoblasts that express hhex and
prox1 in VPA-treated embryos at this stage. In addition, hepatic
duct (the furrow between liver bud and the adjacent esophagus,
thin green arrow) was not obvious and swim bladder was not
visible under VPA (Fig. 4O vs. P). Furthermore, hepatoblasts
differentiation into hepatocytes has yet to occur as the liver
differentiation marker Cp was not expressed in liver until 4 dpf
under continuous VPA (Fig. 1B and Table 1B). These results
show that endoderm cells remain competent to become
hepatoblasts and bud to form liver after 28 hpf and hepatoblasts
remain competent to differentiate into hepatocytes after 4 dpf,
consistent with earlier reports (Shin et al., 2007).
When VPAwas transiently present from 6 to 24 hpf, 50% of
embryos have no hhex expression at 32 hpf and 0% embryos
have Cp expression (Table 1B). HDACs are therefore crucial
for liver specification from endoderm. Transient VPA treatment
from 6 to 18 hpf which led to delay in lfabp expression (liver
only appeared at 4 dpf) in transgenic line also supported a role
of HDACs in inhibiting hepatoblast specification from
endoderm cells (Table 1A). It seems that hepatoblast determina-
tion occurs much earlier than the initial appearance of liver
primordium from 24 hpf. This is consistent with the finding that
Bmp and Fgf signaling is required for liver specification from
18 to 24 hpf (Shin et al., 2007).
When VPA was present from 24 to 36 hpf transiently
(hepatoblast already specified), Cp expression was absent in
70% of embryos at 48 hpf, indicating suppression of hepatoblast
differentiation to hepatocyte. In addition, in the 30% embryos
that do expression Cp, Cp+ liver is much smaller (Table 1B). In
contrast, liver size is nearly normal judged by prox1 and hhex
expression. These results clearly show that VPA inhibits
hepatoblast differentiation to hepatocyte after 24 hpf.
When VPA is present transiently from 48 hpf to 60 hpf, Cp+
liver is also small at 3 dpf (Table 1B). It seems that when
hepatocyte already differentiated to certain extent at 48 hpf and
is Cp+, subsequent presence of VPA suppressed either
additional hepatoblast differentiation to hepatocyte or prolifera-
tion of Cp+ hepatocyte or both, leading to a small Cp+ liver
phenotype at 3 dpf.
All together, the above results clearly show that VPA
inhibited primarily early liver formation including specification,
budding and differentiation, but most likely not hepatocyte
proliferation. However, the possibility that VPA also inhibited
Fig. 4. HDACs are required for early liver development. Expressions of early liver markers were analyzed by WISH in WT and VPA-treated embryos including hhex
(A–D, K, L), prox1 (E–H, M, N) and foxa3 (I, J, O, P). All panels are whole mount pictures except panels B, D, F and H which are tissue sections corresponding to
panels A, C, E and G, respectively, with section planes indicated by red lines. In all panels, liver is indicated by a thick white arrow while pancreas is indicated by a
thick black arrow. Expression of hhex was completely abolished in liver and pancreatic islet (C vs. A) at 24 hpf in VPA-treated embryos while its expression in
intermediate cell mass (ICM) (Avs. C, thin black arrow) remains unaffected. Note that panels A and C were focused on different focal planes with panel A focusing on
the liver region while panel C focusing on the more posterior ICM. White arrowhead indicates hhex expression in notochord (A–D) and black arrowhead in panels C
and D refers to hhex expression in anterior endoderm. At 48 hpf, hhex expression in liver and pancreatic islet was significantly reduced (K vs. L). prox1 expression in
liver region was absent in treated embryos at 28–30 hpf (E vs. G, F vs. H) while its expression was greatly reduced at 48 hpf (M vs. N). The green arrowhead in panel E
indicates interregnal gland which also expresses prox1 at this stage. Initial endoderm thickening at liver region was absent in treated embryos at 28–30 hpf as judged
by foxa3 expression (I vs. J, white arrow). At 48 hpf, a slightly small and compressed liver was observed in VPA-treated embryos while the hepatic duct was still not
well formed (O vs. P, thin green arrow). All imagines are dorsal view, anterior to the left. Scale bar represents 100 μm in panels A, C, E, G, I and J; 20 μm in panels B,
D, F and H; 50 μm in panels K–P. Lv: liver; Pn: pancreas; in: intestine; Sb: swim bladder.
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at 2–3 dpf cannot be completely ruled out at this moment. These
results demonstrate the importance of HDACs in early liver
development and show that short period VPA treatment
generated a long lasting inhibitory effect on subsequent liver
development.
hdac1 has a general role in zebrafish development including
liver and pancreas formation
In mammals, HDACs are a large gene family with 4
members in class I subfamily identified so far (Marks et al.,2003). As VPA inhibits multiple HDACs, it is important to
determine which HDAC plays a dominant role in zebrafish liver
formation. Two zebrafish class I HDAC cDNA sequences
(hdac1 and hdac3) were available from Genbank at the time of
our study. In VPA-treated embryos, both hdac1 and hdac3
mRNAs were down-regulated as determined by qRT-PCR (data
not shown). We therefore set out to investigate the role of these
two hdacs in zebrafish liver formation. Knockdown of each of
the two hdacs by antisense MO injection (6 ng/embryo hdac1
MO and 12 ng/embryo hdac3 MO) effectively inhibited total
HDAC activity in embryos, with hdac1 knockdown more
effective (up to 75% HDAC activity inhibited), indicating the
Table 1B
Summary of the effect of VPA treatment time on liver marker expression
Treatment
start time
Treatment
end time
Embryo
stage for
WISH
Liver marker expression [% embryos]
(liver size)
prox1+ hhex+ cp+
6 hpf 24 hpf 24 hpf – 0% –
6 hpf 28–30 hpf 28 hpf 0% ND –
6 hpf 32 hpf 32 hpf ND ND 0%
6 hpf 48 hpf 48 hpf 100% (small) 100% (small) 0%
6 hpf 3 dpf 3 dpf ND ND 0%
6 hpf 4 dpf 4 dpf ND ND 100%
(small)
6 hpf 24 hpf 32 hpf 100% (small) 50% (small) 0%
24 hpf 36 hpf 48 hpf 100%
(marginal small)
100%
(marginal small)
30%
(small)
48 hpf 60 hpf 3 dpf ND ND 100%
(small)
ND: not determined. “–”: not applicable. Number of embryos in each treatment
is 30–150. VPA used is 20 μM.
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zebrafish embryos (Fig. 5).
Zebrafish hdac1 mutant has been isolated and is embryonic
lethal. hdac1 is required for neuronal specification during
zebrafish CNS development (Cunliffe, 2004; Cunliffe and
Casaccia-Bonnefil, 2006), craniofacial cartilage development
(Pillai et al., 2004), and retinal neurogenesis (Yamaguchi et al.,
2005). However, the role of hdac3 in zebrafish development
has not been investigated.
Each gene was individually knocked down in Tg(lfabp:RFP;
elaA:EGFP) by antisense MO. As shown in Fig. 6a, hdac1
morphants showed similar phenotype as hdac1 mutantsFig. 5. hdac1 is responsible for the majority of HDAC enzymatic activity compared
individual HDAC with antisense morpholino, total HDAC enzymatic activity was
morphants showed a dramatic reduction in total HDAC enzymatic activity with almo
25–30% reduction compared to 5 bp mismatch morpholino injected embryos in both W
artificial fluorescent unit (AFU)/μg of total embryo protein.reported earlier with curved body, smaller head, craniofacial
and eye defect as well as severe cardiac edema (Fig. 6a, panels
B and D). The 5 bp mismatch mutant MO (control) at the same
concentration did not produce any of these defects (Fig. 6a,
panels A and C). At 3 dpf, RFP+ liver was observed in hdac1
morphants (70% of injected embryos, n=150), with certain
embryos showing a somewhat smaller liver (Fig. 6a, panel B
and Fig. 9C). However, liver failed to grow to the same size
from 3 dpf to 5 dpf compared to control embryos (Fig. 6a,
panels B, F and H). At the MO dose of 6 ng/embryo, most of the
embryos could develop and survive until 4–5 dpf. Morphants
developed at normal pace up to 48 hpf, but subsequent
development was delayed for up to 24 h compared to control.
ISV was only minimally affected in these morphants as
observed in Tg(fli-1:EGFP), but SIV was not formed (Fig. 6a,
panel D; 40% of injected embryos, n=100). Morphants have
no blood circulation and severe edema formed from 3 dpf
onward, making live fluorescent imaging in the transgenic line
very difficult. We therefore analyzed exocrine pancreas
development by elaB expression using WISH. As shown in
Fig. 6b, exocrine pancreas was also severely suppressed in
hdac1 morphants while the endocrine pancreas shown by
insulin expression was not affected at all the stages observed
(Fig. 6b, panels D, F and H). These morphants could not
survive beyond 5 dpf. Higher amount of hdac1 MO killed the
embryos at earlier stages.
Therefore, it seems that hdac1 is a crucial gene that plays a
global and general role in zebrafish embryonic development and
knockdown of hadc1 generated severe embryonic defects and
high amount of MO leads to death of the embryos at early
developmental stages. In addition to liver and exocrine pancreas
formation, hadc1 is also critical for neurogenesis, eyeto hdac3 in zebrafish embryos. To check the effectiveness of knocking-down
measured by the fluorescent based HDAC enzymatic activity at 3 dpf. hdac1
st 75% of HDAC activity suppressed while hdac3morphants only showed about
T and Tg(lfabp: RFP; elaA:EGFP) background. HDAC activity is indicated by
Fig. 6. Role of hdac1 in zebrafish liver, pancreas and blood vessels development. (a) Liver development in hdac1 morphants (6 ng/embryo MO) was analyzed in Tg
(lfabp:RFP; elaA:EGFP) from 3 dpf to 5 dpf. Control embryos were injected with the same amount of hdac1 5 bp mismatch MO. Liver (thick white arrow) formed
relatively normal in hdac1 morphants at 3 dpf (A, B). However, its subsequent growth was reduced compared to control embryos (E–H). Angiogenesis was analyzed
in Tg(fli-1:EGFP) at 3 dpf. SIVs were absent (thin white arrow, D) while ISV defects were mild and rare (thin red arrow, C and D). hdac1morphants exhibited global
embryonic defects with severe cardiac edema, small head and eyes as well as absence of craniofacial cartilage structures (B–H). Scale bar is 100 μm. (b) Zebrafish
pancreas development in hdac1 morphants was analyzed by elastase B (A, B) and insulin (C–H) expression through WISH in hdac1 morphants with 5 bp mismatch
MO injected embryos as control (Con.). Exocrine pancreas (white arrow) was significantly reduced at 5 dpf (A, B) but endocrine pancreas formation (black arrow) was
not affected (C–H). All images are dorsal views, anterior to the left. Scale bar is 100 μm.
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angiogenesis.
hdac3 is specifically required for liver development in zebrafish
In contrast to hdac1 morphants, hdac3 morphants presented
normal head and body shape with no cardiac edema at 3 dpf
(even with up to 4 times more MO injected comparing to hdac1
morphants). A smaller liver appeared at 3 dpf (Fig. 7a, panel B),
and it grew somewhat subsequently up to 5 dpf but remained
smaller comparing to control, resembling low concentration VPA
treatment (5 μM or 1 μM) (Fig. 7a, panel B, F and H). Similar to
VPA treatment, liver size was reduced about 50% in hdac3
morphants at 5 dpf as determined by the total number of liver
cells (Fig. S2). Angiogenesis defects were obvious, and dose-
dependent on the amount of hdac3 MO injected (Fig. 7a, panel
D). A second hdac3 MO targeting the 5′-UTR also showed
similar dose-dependent defects on liver development, confirming
the role of hdac3 in liver growth (data not shown). Blood
circulation was normal up to 3 dpf but became slower by 5 dpf. A
mild cardiac edema appeared on 4 dpf (Fig. 7a). Heart presented a
thin tube shape without looping at 5 dpf (data not shown).The liver defects in hdac3 morphants observed in Tg(lfabp:
RFP, elaA:EGFP) were verified by Cp expression. As shown in
Fig. 7b, Cp expression in hdac3 morphants was absent in the
liver region at 32 hpf and 48 hpf (white arrow) whereas its
expression in YSL was not affected (white arrowhead). Cp
expression in liver starts from 3 dpf in morphants, but its
expression was reduced compared to control embryos from
3 dpf to 5 dpf (Fig. 7b, panels F and H). Surprisingly, both
exocrine and endocrine pancreas formation and growth were not
affected in hdac3 morphants as shown by elaA:EGFP expres-
sion in transgenic line, and elastase B expression in WT
embryos for exocrine pancreas (Fig. 7c, panel D) and insulin
expression for endocrine pancreas (Fig. 7c, panels F, H and J).
These results indicate that hdac3 is specifically required for
liver formation.
To analyze the role of hdac3 in early liver formation,
expression of early liver markers hhex, prox1 and foxa3 was
analyzed in hdac3 morphants. Expression of hhex in our local
wild type embryos was first detected at about 24 hpf. Reduced
hhex expression was observed in liver region of hdac3
morphants at 28–30 hpf and 48 hpf (40–50% of morphants,
n=150) (Fig. 8A vs. B, C vs. D) (white arrow), whereas hhex
Fig. 7. hdac3 is specifically required for liver formation in zebrafish. (a) hdac3 was knocked down by antisense morpholino (12 ng/embryo) in Tg(lfabp:RFP; elaA:
EGFP) and liver formation was observed from 3 dpf to 5 dpf. Control (Con.) embryos were injected with 5 bp mismatch antisense morpholino. Blood vessels
formation was monitored in Tg(fli-1:EGFP) at 3 dpf. Liver (thick white arrow) was present at 3 dpf, but its size is much smaller (Avs. B). In addition, it failed to grow
from 3 dpf to 5 dpf or reduced growth was observed compared to control embryos (E–H). ISV (thin white arrow) was disrupted. All the images are lateral view, anterior
to the left. Scale bar represents 100 μm for all panels except panels C and D which is 50 μm. (b) Liver formation in hdac3 morphants monitored by WISH with liver
marker Ceruloplasmin (Cp) at 32 hpf (A, B), 2 dpf (C, D), 3 dpf (E, F) and 5 dpf (G, H). In hdac3morphants, Cp expression (white arrow) was absent up to 2 dpf (A,
D) whereas a reduced liver was observed at 3 dpf (E, F) and 5 dpf (G, H). All images are dorsal view, anterior to the left. Arrowhead indicates Cp expression in YSL.
(c) hdac3 is not involved in pancreas formation. Exocrine and endocrine pancreas were monitored by GFP in Tg(lfabp:RFP; elaA:EGFP) and WISH with insulin,
respectively. Control embryos were injected with same amount of 5 bp mismatch morpholino. Both exocrine pancreas (white arrowhead, A–D) and endocrine pancreas
(black arrow, E–J) were not affected in hdac3morphants, whereas liver (red fluorescence, white arrow) was affected (Avs. B). All the images are dorsal view, anterior
to left. Scale bar is 50 μm.
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black arrow). prox1 expression also showed a reduced liver in
hdac3 morphants, although the liver defect is milder than that
of VPA-treated embryos (Fig. 8E vs. F, G vs. H, 50% of
morphants, n=100). Anterior endoderm thickening in liver
region (white arrow) which represents the initial stage of liver
budding was absent at 28–30 hpf as indicated by foxa3
expression (Fig. 8I vs. J, 40% of morphants, n=200) while theanterior intestinal expression was not affected. These results
indicate that at 28–30 hpf, fewer hepatoblasts formed from
endoderm in hdac3 morphants. In addition, although liver
primordium exists (hhex+prox1+) and anterior endoderm
looping occurred, liver budding is delayed in these morphants.
At 48 hpf, foxa3 expression indicated that liver has budded
from endoderm, although it is slightly smaller (Fig. 8K vs. L,
40% of morphants, n=200). Swim bladder was absent at this
Fig. 8. hdac3 is required for early liver formation. WISH with three hepatoblast markers hhex (A–D), prox1 (E–H) and foxa3 (I–L) was analyzed in hdac3morphants.
At 28–30 hpf, hhex expression in liver (white arrow) was greatly reduced in hdac3morphants (Avs. B). It remained reduced at 48 hpf (C vs. D) whereas its expression
in pancreatic islet (black arrow) was less affected. prox1 expression was reduced in liver region at 28–30 hpf (white arrow, E vs. F) and at 48 hpf (G vs. H), while its
expression in mesoderm (E and F, green arrow) and pancreas (G and H, black arrow) is less affected. At 28–30 hpf, liver budding (shown as anterior endoderm
thickening) was absent in hdac3MO (I vs. J, white arrow) as judged by foxa3 expression and a reduced liver region was observed at 48 hpf (K, L). foxa3 expression in
pancreas region (I, J, black arrow and Pn in K, L) was less affected in both stages. Swim bladder was absent at 48 hpf in hdac3MO (K vs. L). Lv: liver; Pn: pancreas;
in: intestine; Sb: swim bladder. Scale bar represents 100 μm in panels A–F; 50 μm in panels G–L.
Fig. 9. Double knockdown of hdac1 and hdac3 leads to severe defects in
embryonic development including liver and blood vessel. Double knockdown of
hdac1 and hdac3 was performed by simultaneous injection of both MOs (hdac1
MO at 3 ng/embryo; hdac3 MO at 12 ng/embryo) into Tg(lfabp:RFP; elaA:
EGFP) and Tg(fli-1:EGFP) embryos and was compared with the same quantity
of 5 bp mismatch morpolinos (control, A–B). Liver (thick white arrow) was
absent at 3 dpf and blood vessels (thin white arrow) were severely disrupted.
Embryos were severely deformed in the double knockdown morphants (G, H)
and they cannot survive beyond 3 dpf. All images were side view, with anterior
to the left. Scale bar is 100 μm.
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pancreas was less affected (Fig. 8K vs. L). prox1 expression
remained reduced in liver up to 5 dpf, indicating a small liver
(data not shown). These phenotypes are similar to that of low
concentration VPA-treated embryos. They confirmed hdac3's
role in early liver formation including hepatoblast specification
and liver budding.
Since hdac3 affects liver formation, we analyzed its
expression pattern. As shown in Fig. S3, hdac3 is widely
expressed during the first day of embryonic development with
high level expression in the brain. This expression pattern is
similar to that of hdac1 in the same period (Cunliffe, 2004).
This wide-spread expression gradually becomes restricted in the
anterior brain with very high expression in the eye. A low level
expression was observed in the anterior endoderm at 2 dpf. By
3 dpf, high level expression in the intestinal bulb and low level
expression in liver were observed while the expression in brain
remains. By 5 dpf, it is expressed at high level in the intestine,
but the liver expression disappears. VPA did not affect hdac3
expression in the brain; however, it abolished hdac3 expression
in liver at 3 dpf and reduced its expression in the intestine from
3 dpf to 5 dpf (Figs. S3F, H and J).
The above results indicate that hdac3 plays an important role
in liver development. It is expressed transiently in the liver
region and knockdown of its expression resulted in delay in
liver development. Comparing to hdac1, zebrafish embryos can
tolerate high amount of hdac3MO (3–4 times more than hdac1
MO) without causing severe gross developmental defects or
embryonic death while inhibiting liver formation and angiogen-
esis more profoundly and specifically.
Double knockdown of hdac1 and hdac3 leads to severe
interruption of early embryonic development in zebrafish
To investigate the combined impact of double hdac1 and
hdac3 knockdown, we injected both morpholinos together
(3 ng/ml hdac1 MO and 12 ng/embryo hdac3 MO).
As shown in Fig. 9, double knockdown resulted in severe
abnormalities in almost all embryos including no circulation,curved body, small head and severe cardiac hypertrophy, similar
to hadc1 single knockdown morphants (Fig. 9G). Severe
angiogenesis defects in trunk blood vessels are observed in 90%
of injected embryos (n=200), much more severe than single
knockdown of either gene (Fig. 9D). No RFP+ liver could be
detected at 3 dpf (Fig. 9G). These morphants could not survive
more than 3 dpf. In contrast, control embryos (injected with
same amount of 5 bp mismatch MOs) developed normally
(Figs. 9A and B). It is noted that the amount of hdac1
Table 2
Summary of rescue effect of the small liver phenotype under VPA treatment by
microinjection of hdac1 or hdac3 mRNA or both
Without VPA With VPA
No. of
embryos
Liver size
at 5dpf
No. of
embryos
Liver size
at 5 dpf
Control 300 Normal 350 Small (100%)
hdac1 mRNA (0.3 ng) 250 Normal 250 Not rescued,
242 (95%)
Partial rescued,
8 (4%)
hdac3 mRNA (0.3 ng) 250 Marginally
larger
200 Not rescued,
80 (40%)
Partial rescued,
120 (60%)
hdac1+ hdac3 mRNA
(0.3+0.3) ng
200 Normal 200 Not rescued,
80 (40%)
Partial rescued,
120 (60%)
VPA used is 10 μM.
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experiments (3 ng/embryo) due to severe growth arrest and
embryo death in early stages while hdac1 single knockdown
could tolerate MO dose of 6 ng/embryo. However, hdac1 single
knockdown using 3 ng/embryo MO generated morphological
defects of similar severity as 6 ng/embryo MO (Figs. 6a and 9).
These results indicate that both these hdac genes play critical
roles in early zebrafish embryonic development including liver
and vascular development.
Overexpression of hdac3 but not hdac1 partially rescued VPA
induced liver defects in zebrafish embryos
To further confirm if VPA induced liver/exocrine pancreas
defects mainly through suppressing hdac3, hdac3 was over-
expressed by mRNA microinjection (0.3 ng/embryo) into VPA-
treated embryos. Under low concentration of VPA (10 μM),
60% (n=200) of the injected embryos were rescued to some
extent in liver development (Fig. 10, compare B and F; Table 2).
In contrast, injection of same amount of hdac1 mRNA could
only rescue about 4% (n=250) of embryos (Fig. 10, compare B
and D; Table 2). Simultaneous injection of both hdac1 and
hdac3 mRNA (0.3 ng/embryo of each mRNA) rescued the
VPA liver phenotype to similar extent of hdac3 mRNA alone
(n=200) (Fig. 10, compare B and H; Table 2). Higher amount ofFig. 10. hdac3 mRNA partially rescued the liver defects in VPA-treated
embryos while hdac1mRNA could not. 5′-capped mRNAs of hdac1 and hdac3
were synthesized in vitro and used to rescue the liver defects in VPA-treated
embryos in Tg (lfabp:RFP, elaA:EGFP) by microinjection. Overexpression of
hdac1 mRNA (0.3 ng/embryo) did not generate any obvious impact on liver
development (C vs. A) and hdac1 mRNA failed to rescue the liver defects in
VPA-treated embryos (D vs. B). In contrast, hdac3 mRNA (0.3 ng/embryo) led
to a slight increase in liver size compared to control (E vs. A). It also readily
rescued the small liver defects in VPA-treated embryos although not to the same
size of the control at the doses analyzed (F vs. B). Injection of both hdac1 and
hdac3mRNA together (0.3 ng/embryo each) rescued the liver defect under VPA
to similar extent as hdac3mRNA alone (H vs. B). All images are lateral view of
5 dpf embryos, anterior toward the left. Scale bar is 100 μm.hdac1 or hdac3 mRNA either singularly or together leads to
severe abnormalities and embryonic death from early stages,
making assessment of its effect on liver formation impossible.
hdac3 overexpression in control embryos generated a marginal
but consistent increase in liver size while hdac1 mRNA is less
effective (Fig. 10, compare A vs. C, and A vs. E). Double
injection of both mRNAs together into control embryos leads to
marginal increase in liver size to similar extent as hdac3 mRNA
alone (Fig. 10G). These results confirmed that hdac3 is more
specifically required for liver development in zebrafish
embryos. It is noted that, at higher VPA concentration
(20 μM), hdac3 overexpression could no longer rescue VPA
induced liver defects (data not shown).
hdac3 promotes liver growth/expansion by suppressing growth
differentiation factor 11 (gdf11) gene
It has been previously reported that HDAC3, but not other
class I HDACs, specifically represses gdf11 expression in
cultured fibroblasts by deacetylating histone H3 on gdf11
promoter (Zhang et al., 2004). HDAC inhibitor TSA has been
shown to suppress HDAC3 expression which leads to up-
regulation of gdf11 gene in cell culture. The secreted Gdf11 is a
member of the transforming growth factor β family that inhibits
cell proliferation. It is involved in multiple developmental
processes in mouse and chicken, including neurogenesis,
chondrogenesis, myogenesis and pancreas development
(Gamer et al., 2001; Harmon et al., 2004; Wu et al., 2003).
However, its role in liver formation has not been studied in any
species.
Using qRT-PCR, we observed that VPA up-regulated gdf11
mRNA by at least 2-folds at 24 hpf, and up to 4-folds by 2 dpf.
The up-regulation lowered to 2-folds at 3 dpf before returning
back to control levels by 4 dpf (Fig. 11A).
Since GDF11 is a direct and unique target of HDAC3 in
cultured mammalian cells, it is possible that hdac3 influences
liver organogenesis in zebrafish embryos by targeting this gene.
If so, knockdown of gdf11 in hdac3 morphants would be
Fig. 11. (a) VPA induced gdf11 expression in zebrafish embryos. WT zebrafish embryos were treated with VPA at shield stage and total RNAwas extracted at various
developmental stages. gdf11 mRNA level was analyzed by real-time RT-PCR. gdf11 mRNA level of the control embryos at each stage is set to be 1. (b) gdf11
neutralized the liver defects induced by hdac3. To confirm that hdac3 suppresses liver growth by suppressing gdf11 gene, a double knockdown of hdac3 and gdf11 as
well as simultaneous overexpression of both genes was performed. Knockdown of gdf11 neutralized the effect of hdac3 knockdown (D vs. B). On the other hand,
overexpressions of gdf11 lead to a small liver phenotype similar to hdac3 morphants (G vs. E). Simultaneous overexpression of both genes leads to the neutralization
of the liver phenotype induced by overexpression of gdf11 alone (H vs. F), although liver in the double overexpression embryos was often not restored to the same size
of the control (compare E and H). Liver is indicated by white arrow. All images are lateral view of 5 dpf embryos, anterior to the left. Scale bar is 100 μm.
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shown in Fig. 11b, liver size was wholly or partially restored in
about 40% (n=50) of embryos when hdac3 and gdf11 were
knocked down simultaneously (compare panels B vs. D).
Knockdown of gdf11 alone showed no obvious impact on liver
(Fig. 11b, panel C). On the other hand, overexpression of gdf11
by mRNA microinjection generated a small liver phenotype at
5 dpf in a dose-dependent manner (Fig. 11b, panel G). About
10% of embryos were also much smaller in overall body size
compared to control embryos when gdf11 is overexpressed (data
not shown). Interestingly, liver formed and developed normally
in most of the gdf11 overexpressed embryos up to 3 dpf (data not
shown). Therefore, gdf11 seems to be specifically involved in
suppressing the growth/expansion phase of liver development in
zebrafish, consistent with its role as a cell proliferation inhibitor.
In contrast, hdac3 overexpression leads to a slight increase in
liver size (Fig. 11b, panel F vs. E). As expected, the small liver
defects in gdf11 overexpressed embryos were neutralized by
simultaneous hdac3 overexpression (Fig. 11b, panel H vs. G),
consistent with the reported role of hdac3 as a repressor of gdf11
gene expression.
To confirm the role of gdf11 in liver development, we
analyzed its expression pattern. Overall, gdf11 gene is expressed
at very low levels and its expression further declined from 3 dpfonward, requiring prolonged staining to show positive signal. In
VPA-treated embryos and hdac3 morphants, gdf11 expression
in all domains was up-regulated (Figs. S4A and B). At 26–
28 hpf, gdf11 mRNA was localized to brain and eyes with no
expression in the posterior part of the embryo (Fig. S4A). From
2 dpf onward, it is expressed in the pharyngeal arch region, the
pectoral fin bud and several defined bilateral ventral areas
anterior to the fin bud. By 4 dpf, expression in the notochord is
obvious. Although no liver or pancreas expression could be
detected in WT embryos in whole mount by WISH, expression
was observed in liver at 48 hpf or in the adjacent mesoderm at
3 dpf under VPA by tissue sections (Figs. S4A, D' vs. D, F' vs.
F). At 5 dpf, gdf11 expression was essentially undetectable. No
gdf11 expression can be detected in embryos injected with
hdac3 mRNA in all stages, consistent with hadc3 being a
repressor of gdf11 transcription (data not shown). All together,
this expression pattern supports a link between gdf11 and hdac3
in zebrafish development.
gdf11 is involved in zebrafish exocrine pancreas development
GDF11 has been reported to regulate the production and
maturation of islet progenitor cells in mouse endocrine pancreas
development. One report showed that Gdf11 knockout mice
Fig. 12. gdf11 negatively control exocrine pancreas growth in zebrafish. Pancreas formation was analyzed in gdf11 morphants by insulin (A–F) and elaB (G–H)
expression. The endocrine pancreas formation (black arrow) was basically normal in gdf11 MO compared to 5 bp mismatch control morpholino injected embryos. A
slight increase in insulin positive area was observed in about 10% of gdf11MO at 5 dpf (F). elaB positive exocrine pancreas (white arrow) showed obvious increase in
the majority of gdf11 MO at 5 dpf (H). Panels A–F are dorsal view while panels G–H are lateral view, anterior to the left. Scale bar is 100 μm.
350 M. Farooq et al. / Developmental Biology 317 (2008) 336–353harbor increased numbers of islet progenitor cells despite
having a reduced mature β-cell numbers (Harmon et al., 2004).
On the other hand, another report indicated a conflicting result
of normal number of endocrine cells in these mice despite an
increase in progenitors (Dichmann et al., 2006). We analyzed
whether gdf11 is involved in zebrafish pancreas development in
gdf11morphants. Normal insulin expression in gdf11morphants
showed that endocrine pancreas formation was generally not
affected. Although insulin expressing cells were localized
somewhat more posterior at 2 dpf in the trunk compared to 5 bp
mismatch MO injected embryos (Figs. 12A and B; 80% of
injected embryos, n=50), its expression and localization were
similar to control at 3 dpf (Figs. 12C and D). At 5 dpf, a slightly
larger endocrine pancreas was observed in about 10% of gdf11
morphants (n=50) whereas the remaining embryos presented
normal size endocrine pancreas (Figs. 12E and F). While
exocrine pancreas formed at the normal developmental stage, an
expanded elaB positive area was observed at 5 dpf in almost
80% of injected embryos (n=100) (Figs. 12G–H), suggesting a
repressive role for gdf11 in exocrine pancreas growth.
Discussion
In this work, we showed for the first time that HDACs are
required for liver and exocrine pancreas development in
zebrafish. Inhibiting HDACs by VPA interfered with early
liver development including specification of endoderm cells to
hepatoblasts, budding of liver primordium from anterior
endoderm and differentiation of hepatoblasts to hepatocytes.
In VPA-treated embryos, absence/delay of expression was
observed for three undifferentiating liver markers (hhex, prox1
and foxa3) and two liver differentiation makers (Cp and lfabp),
indicating disruption of liver specification and differentiation.
Transient VPA treatment from 6 hpf to 18 hpf leads to delay in
liver development in Tg(lfabp:RFP; elaA:EGFP) embryos,
with RFP+ liver first appearing at 4 dpf (Table 1A). When VPA
was transiently present from 6 hpf to 24 hpf, 50% of embryos
have no hhex expression at 32 hpf (Table 1B). These results
demonstrate that HDACs are required for hepatoblast determi-
nation from endoderm in stages much earlier than the formationof its primordium around 24 hpf. Our results are consistent with
the recent finding that bmp and fgf signaling is required for liver
specification from 18 hpf to 24 hpf (Shin et al., 2007).
Under continuous VPA treatment, expression of hhex, prox1
and foxa3 in liver was observed from 48 hpf onward but Cp
expression in liver was not observed until 4 dpf, demonstrating
the presence of hepatoblasts at 2 dpf, but lack of differentiation
of these cells until 4 dpf. When present from 24 hpf to 36 hpf
transiently (hepatoblast already specified), 70% of embryos at
48 hpf lack Cp expression while a small Cp+ liver was observed
the remaining embryos. However, liver size is nearly normal
judged by prox1 and hhex expression in these embryos. These
results clearly indicate that VPA also suppressed hepatoblasts
differentiation to hepatocytes, resulted in absence or less
number of differentiated hepatocytes. They also show that
endoderm cells remain competent to become hepatoblasts after
24 hpf and hepatoblasts remain competent to differentiate into
hepatocytes after 4 dpf.
When present from 48 hpf to 60 hpf or 3 dpf (Cp+
hepatocytes already present), VPA leads to a small liver at 3 dpf
(Tables 1A and B). Even though VPA is removed subsequently,
liver still remains small up to 5 dpf. These results suggest that
VPA either suppressed additional hepatoblast differentiation to
Cp+ hepatocyte from 48 hpf onward, proliferation of Cp+
hepatocyte or both. Furthermore, inhibiting HDACs during 2–
3 dpf seems to have a long lasting effect on subsequent liver
growth/expansion, possibly through modulation of chromatin
structure. When VPA is present from 3 dpf onward, liver
developed normally and grew to normal size, suggesting a lack
of inhibition on hepatocyte proliferation when HDACs are
inhibited after 3 dpf. Further studies of hepatocyte proliferation
under VPA are required to clarify if VPA also inhibited
hepatocyte proliferation when present continuously or transi-
ently between 2 dpf and 3 dpf.
We used VPA concentration at 20 μM or less which showed
minimum developmental delay and no gross developmental
defects during early developmental stages. The morphological
features of the embryos before 3 dpf were comparable with
control embryos (Fig. S1). Circulation was normal in treated
embryos up to 4 dpf, and slowed down or stopped at 5 dpf in the
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embryos was comparable with untreated control up to 5 dpf.
Therefore, the liver and exocrine pancreas defects observed in
VPA-treated embryos were not due to the non-specific
teratogenic or toxic affect. Indeed, VPA concentration less
than 30 μM has been previously reported to be non-teratogenic
in zebrafish embryo (Gurvich et al., 2005; Herrmann, 1993). We
further showed that the liver defects are due to inhibition of
HDACs using a structurally different HDAC inhibitor TSA and
a non-active VPA analog valpromide.
VPA also effectively disrupted embryonic angiogenesis
(Figs. 1 and 3). Similar although milder angiogenesis defects
were observed in hdac1 mutant, hdac1 morphants (Pillai et al.,
2004; Isenberg et al., 2007), and hdac3 morphants (this work).
Double knockdown of hadc1 and hadc3 generated severe
angiogenesis defects, similar to high concentration VPA
treatment (Fig. 9 and data not shown). These results
demonstrate the importance of these two hdacs in embryonic
blood vessel formation. Indeed, knockdown of hdac1 gene
suppressed about 75% of total HDAC activity while knock-
down of hdac3 leads to a reduction of about 25% of total
HDAC activity in zebrafish embryos (Fig. 5). One possible
mechanism through which VPA inhibits angiogenesis in
zebrafish embryos is suppression of vegf expression (our
unpublished data).
We demonstrated here that the liver defects induced by VPA
in zebrafish embryos are not a result of its inhibition of
angiogenesis. At similar level of angiogenesis inhibition,
specific chemical angiogenesis inhibitors did not interfere
with liver formation (Fig. 3). Altogether, these results supported
a role of HDACs but not vascularization in liver formation. This
is consistent with a previous report of normal liver budding in
zebrafish cloche mutant in which the vasculature is severely
defective (Field et al., 2003).
Through antisense MO knockdown, we further demonstrated
that both hdac1 and hdac3 are required for liver formation.
However, while hdac1 is more globally required for embry-
ogenesis, hadc3 is more specifically required for liver
formation. Similar to hdac1 mutant, severe developmental
defects were observed in hdac1 morphants, consistent with the
significant contribution of this gene to total HDAC enzymatic
activity in zebrafish embryos (Fig. 5). On the other hand,
knockdown of hdac3 specifically perturbed liver formation
without affecting pancreas development. In hdac3 morphants,
expressions of earlier liver markers (hhex, prox1 and foxa3) as
well as differentiation markers (Cp and lfabp) in liver region
were delayed or reduced in similar fashion as in low
concentration VPA (10 μM or 5 μM) -treated embryos,
indicating the requirement of this gene in liver specification,
budding and differentiation. In hdac3 morphants, a small liver
is present at 3 dpf. At 5 dpf, the number of liver cells was
reduced to about 50% of control embryos (Fig. S2). However,
since higher doses of VPA induced more severe defects in liver
formation, it is likely that additional hdacs are also involved.
Indeed, hdac1 morphants also showed defects in liver growth
(Fig. 6). However, due to more global function of hdac1, these
morphants presented severe gross developmental defects from3 dpf onward. It is possible that the liver defect in hadc1
morphants is a secondary effect of other developmental defects
in these embryos. To identify more target genes important for
liver and pancreas development, a microarray approach has
been adopted to identify genes influenced by low level VPA
during a relevant developmental period (data will be presented
elsewhere).
We further showed that gdf11 is a possible target of hdac3 in
liver development in zebrafish. Knockdown of gdf11 rescued
the small liver phenotype in hadc3 morphants (Fig. 11) while
overexpression of gdf11 suppressed liver growth, generating a
small liver phenotype resembling hdac3 morphants, possibly
by suppressing hepatocyte proliferation (Fig. 11). Most
importantly, overexpression of hdac3 could partially rescue
the liver growth defect in gdf11 overexpressing embryos as well
as in VPA-treated embryos, consistent with the result that gdf11
mRNA expression was up-regulated by VPA. However,
simultaneous overexpression of both hadc1 and hdac3 did not
lead to more efficient rescue of VPA suppressed small liver
phenotype. Since VPA inhibits multiple HDACs, it is possible
that additional hdac genes in zebrafish are also involved. These
results demonstrate the functional antagonism between hdac3
and gdf11, suggesting that hdac3 may promote liver growth by
suppressing gdf11 gene function in zebrafish. However, since
liver formed normally up to 3 dpf in gdf11 overexpressing
embryos, it is clear that hdac3 also functions through other
target genes.
The Wnt/β-catenin pathway has been shown to be important
in vertebrate liver morphogenesis and overexpression of β-
catenin in chicken leads to 3-fold increase in liver weight
(Suksaweang et al., 2004). In mouse, suppression of β-catenin
resulted in reduced liver cell proliferation (Monga et al., 2003).
Recently, mesodermal Wnt signaling was also shown to
regulate liver specification in zebrafish (Ober et al., 2006). As
HDAC inhibitors such as VPA have been shown to alter Wnt-
dependent gene expression and regulate β-catenin pathway
(Pillai et al., 2004; Wiltse, 2005), the induced defects in
zebrafish liver formation could potentially involve alterations in
Wnt signaling pathways as well.
Histone acetylation has been reported to be a checkpoint for
transduction of FGF signals to induce mesoderm in Xenopus
through transcription factor AP-1 (Xu et al., 2000). AP-1-
mediated mesoderm induction in the animal caps is dramatically
suppressed by the HDAC inhibitor TSA at a dose-dependent
manner. Interestingly, this suppression can be rescued by
ectopic expression of HDAC3 at early stage. Since Bmp and Fgf
signaling is essential for liver specification in zebrafish (Shin et
al., 2007), it will be interesting to know if hdac3 function in
early liver development is linked to Fgf.
VPA also interfered with exocrine pancreas formation. elaB
expression normally starts from about 56 hpf and reach very
high level in pancreas at 4 dpf (Mudumana et al., 2004).
However, in VPA-treated embryos, elaB expression only
appeared at 5 dpf. In contrast, the expression of endocrine
pancreas marker insulin was normal, consistent with the model
that the two parts of the pancreas derive from different
progenitors and evolve differently during development. It has
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arise from a common progenitor within the ventral foregut
endoderm (Deutsch et al., 2001). Recently, fate map analysis of
zebrafish pancreas confirmed that the dorsal pancreas (strictly
endocrine) and ventral pancreas (primarily exocrine) come
mostly from independent cell populations (Ward et al., 2007).
We did not detect any obvious changes in both endocrine and
exocrine pancreas development in hdac3 morphants (Fig. 7).
Early endocrine pancreas development in gdf11 morphants is
also generally normal as indicated by insulin expression pattern
(Fig. 12), although about 10% of morphants showed a slightly
larger endocrine pancreas at this stage. However, exocrine
pancreas was clearly enlarged at 5 dpf in gdf11 morphants as
judged by elaB expression pattern. As the pancreas phenotype
in gdf11 morphants only becomes obvious at 5 dpf, and the fact
that the effectiveness of MO inhibition of gene expression
declines quickly after 3 dpf, whether hdac3 has any role in
pancreas development needs to be further explored.
Recently, epigenetic modifications of DNA and histone by
methylation have been shown to help execute specific
developmental programs, affecting the terminal differentiation
of intestine, exocrine pancreas and retina, but not endocrine
pancreas and liver in zebrafish (Rai et al., 2006). Our data here
clearly support the model that epigenetic modifications of
histone/transcription factors by acetylation/deacetylation are
also regulators of liver organogenesis.
Conclusion
We demonstrated for the first time that HDACs are required
for early liver development in zebrafish embryos including
specification, budding, and differentiation. They are also
involved in exocrine pancreas formation but have no effect on
the development of endocrine pancreas. While hdac1 is more
globally required for embryonic development including liver
and exocrine pancreas, hdac3 is more specifically required for
liver formation. We further show that hdac3 and gdf11 function
antagonistically in liver growth, consistent with earlier reports
that hdac3 negatively regulates gdf11 transcription. gdf11 also
negatively regulates exocrine pancreas growth while its
influence on endocrine pancreas is quite limited. In addition,
we show that vascularization is not required for liver formation
in zebrafish.
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